SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is buzzing with conversation after its recent financial update, which showcased impressive membership growth and an optimistic 2026 outlook, fueling bullish enthusiasm despite concerns over a quarterly performance miss and ongoing uncertainty surrounding broader healthcare policy.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending amid a broad software sector sell-off, fueled by investor concerns that rapidly advancing AI will disrupt or replace traditional SaaS models. While some analysts and market participants argue that AI will enhance core enterprise software and point to a significant government contract, the community remains polarized between those calling it a "generational buying opportunity" and those fearing further valuation compression.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to its strong Q4 earnings beat and robust subscriber growth, alongside recent premium subscription price increases. The community is widely debating if these positive catalysts, coupled with new AI features and video content, can reverse the stock's recent downtrend and its perceived correlation with Netflix's performance, as many consider it oversold.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following strong Q4 earnings and a new share buyback, prompting community debate over its significant stock-based compensation and dilutive practices, particularly as reports circulate about Meta's Instagram developing a rival app.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv (FISV) is actively trending as investors keenly await its earnings report, fueling intense community debate between those who believe the stock is deeply undervalued with a promising turnaround under new leadership, and others bracing for a significant drop mirroring previous disappointments and broader fintech sector headwinds. Significant options activity indicates widespread expectation of a volatile price movement following the announcement.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending after the FDA issued a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns over trial design and efficacy evidence, compounding worries from an earlier clinical hold related to a brain tumor in a related gene therapy. The community is actively debating the severe financial implications of this setback, exacerbated by multiple downgrades, though some hold hope for other pipeline assets like the AbbVie-partnered RGX-314.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending after securing crucial Medicare coverage for its ultra-sensitive Molecular Residual Disease (MRD) test, marking a significant de-risking milestone for the company. The community is highly optimistic about this pivotal step, anticipating substantial revenue growth and further approvals to solidify Personalis's position in the rapidly evolving cancer diagnostics market.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is trending due to the abrupt departures of its CFO and General Counsel amid an ongoing accounting review, delayed SEC filings, and internal control weaknesses, which has the community intensely debating severe credibility risks and drawing comparisons to other companies that faced similar financial reporting challenges.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending lower following mixed guidance for the upcoming quarter and fiscal year, despite reporting stronger-than-expected Q4 earnings. This has ignited a contentious debate among investors, with many fearing AI will render its services obsolete, while others view the pullback as a prime buying opportunity, banking on the company's stated focus on human-plus-AI collaboration.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending following strong Q4 2025 financial results and positive FY26 guidance, bolstered by recent FDA approvals for its oncology blockbusters Enhertu and Datroway, and groundbreaking Phase 3 data for hypertension treatment Baxdrostat. The community is actively discussing the company's strategic direct listing on the NYSE, along with significant investments in US manufacturing and an expanding obesity pipeline in China, all signaling a robust long-term growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned a consensus rating of "Buy" from the eleven analysts that are presently covering the stock, MarketBeat.com...

Tejara Capital Ltd Trims Stock Position in Trevi Therapeutics, Inc. $TRVI

Tejara Capital Ltd cut its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 88.6% in the third quarter, according to its most recent disclosure with the Securities and...

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.5% - Here's Why

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.5% - Time to Sell...

Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) Trevi Therapeutics Announces...

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 6.3% - Here's Why

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.3% - Here's Why...

Flputnam Investment Management Co. Raises Stock Holdings in Trevi Therapeutics, Inc. $TRVI

Flputnam Investment Management Co. grew its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 1,105.4% during the third quarter, according to the company in its most recent...

Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% Higher - Time to Buy?

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Up 5.7% - Should You Buy...

Trevi Therapeutics, Inc. $TRVI Shares Acquired by Vivo Capital LLC

Vivo Capital LLC grew its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 28.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and...

226,381 Shares in Trevi Therapeutics, Inc. $TRVI Bought by Prudential Financial Inc.

Prudential Financial Inc. bought a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities...

Trevi Therapeutics, Inc. $TRVI Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC boosted its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 10.6% in the 2nd quarter, according to the company in its most recent disclosure...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Trevi Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

TRVI
Trevi Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRVI News

TRVITrevi Therapeutics Inc